Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH.
Dooley KE, et al. Among authors: ignatius eh.
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE.
Am J Respir Crit Care Med. 2020.
PMID: 32130866
Free PMC article.
No abstract available.